Oral semaglutide, already approved for type 2 diabetes, led to a reduction in CV events in patients with established ...

Mick Hitchcock, Ph.D., appointed Interim Chief Executive Officer Biomea preparing icovamenib for late-stage clinical development Multiple ...

Lead candidate ARD-101 demonstrated clinical activity and was generally well tolerated in a two-part Phase 2 trial in Prader-Willi Syndrome ...

Lexicon eligible to receive up to $1 billion in upfront and development, regulatory and sales milestone payments, including $75 million in upfront and ...

AstraZeneca has revealed phase 2b results with its oral PCSK9 inhibitor AZD0780, including a more than 50% reduction in ...

EVERSANA is joining more than 20 organisations in Veeva's AI Partner Programme, first launched in April 2024, which provides access to technology and support needed to integrate generative AI (GenAI) ...

Patients without diabetes using GLP-1RAs are less likely to develop glaucoma compared with those who use other weight loss therapies.

Q. I have two sons, 5 and 7. I do not allow my children more than a half hour a day on their iPad. My partner uses screen time as ...